Protalix BioTherapeutics Says Operations Have Not Been Adversely Affected By Current Security Situation In Israel;
Portfolio Pulse from Benzinga Newsdesk
Protalix BioTherapeutics has announced that its operations have not been adversely affected by the current security situation in Israel. The company does not anticipate any disruption to the supply of its products Elfabrio® or Elelyso®.
October 09, 2023 | 11:07 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Protalix BioTherapeutics' operations and product supply remain unaffected by the security situation in Israel. This could maintain investor confidence in the company.
Protalix BioTherapeutics' announcement that its operations and product supply are unaffected by the security situation in Israel is likely to maintain investor confidence. However, the situation is fluid and could change, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100